Références

1. Puig-Barbera J. MF59®-adjuvanted seasonal influenza vaccine. Aging Health. 2009;5(4):475-81.

2. El Sahly H. MF59TM as a vaccine adjuvant: a review of safety and immunogenicity. Expert Review of Vaccines. 2010;9(10):1135-41.

3. Novartis Vaccines Inc. Fluad® product monograph. Cambridge (MA): Novartis Vaccines Inc;2010.

4. Iob A, Brianti G, Zamparo E, et al. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiology & Infection. 2005;133(4):687-93.

5. Puig-Barbera J, Diez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21.

6. Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine. 2004;23(3):283-9.

7. Mannino S, Villa M, Apolone G, et al. Effectiveness of influenza vaccination with Fluad® versus a subunit influenza vaccine. Poster presented at: Canadian Geriatrics Society 31st Annual Scientific Meeting. 2011:Vancouver.

8. Banzhoff A, Pellegrini M, Del Giudice G, et al. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses. 2008;2(6):243-9.

9. Committee for Proprietary Medicinal Products (CHMP). Note for guidance on harmonisation of requirements for influenza vaccines. 1997.

10. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177-84.

11. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19(17-19):2673-80.

12. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25):4123-9.

13. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine. 2008;26(12):1525-9.

14. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clinical & Developmental Immunology. 2010;2010:517198.

15. Baldo V, Baldovin T, Floreani A, et al. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol. 2006;21(11):843-5.

16. Baldo V, Menegon T, Bonello C, et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine. 2001;19(25-26):3472-5.

17. de Bruijn I, Meyer I, Gerez L, et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007;26(1):119-27.

18. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine. 1999;17(23-24):3094-101.

19. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol. 2001;17(2):135-40.
20. Giammanco G, Coniglio M, Pignato S, et al. Immunogenicity and tolerability of two subunit influenza vaccines in patients with chronic obstructive bronchopneumopathy. J Prev Med Hyg. 2005;46(3):85-7.

21. Li R, Fang H, Li Y, et al. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing. 2008;5:2.

22. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 1999;17(2):99-104.

23. Pregliasco F, Mensi C, Serpilli W, et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano). 2001;13(1):38-43.

24. Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection. 2004;32(4):191-8.

25. Sindoni D, La Fauci V, Squeri R, et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J Prev Med Hyg. 2009;50(2):121-6.

26. Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine. 2003;21(11-12):1268-74.

27. Van Damme P, Arnou R, Kafeja F, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis. 2010;10:134.

28. de Roux A, Marx A, Burkhardt O, et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine. 2006;24(10):1537-42.

29. Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006;24(16):3063-5.

30. Menegon T, Baldo V, Bonello C, et al. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol. 1999;15(6):573-6.

31. Iorio AM, Neri M, Lepri E, et al. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home. Vaccine. 2006;24(44-46):6615-9.

32. Camilloni B, Neri M, Lepri E, et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine. 2010;28(47):7536-41.

33. Baldo V, Baldovin T, Floreani A, et al. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine. 2007;25(20):3955-61.

34. Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15(2):253-9.

35. Frey S, Poland G, Percell S, et al. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine. 2003;21(27-30):4234-7.

36. Gabutti G, Guido M, Durando P, et al. Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients. J Int Med Res. 2005;33(4):406-16.

37. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant. 2005;24(5):588-92.
38. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65.

39. Tsai T, Kyaw MH, Novicki D, et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. Vaccine. 2010;28(7):1877-80.